prmt5 inhibitor tng456
Generic: PRMT5 Inhibitor TNG456
prmt5 inhibitor tng456: developed by 1 company · 1 clinical trial tracked.
prmt5 inhibitor tng456 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect prmt5 inhibitor tng456 to TNGX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could prmt5 inhibitor tng456 → TNGX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Tango Therapeutics, Inc. (TNGX) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Primary endpoint: Phase 1 Maximum Tolerated Dose
Interventionalopen191 targetStarted 2025-03Completion 2027-0915 sites · United StatesTango Therapeutics, Inc.
Frequently asked questions
Who is developing prmt5 inhibitor tng456?
prmt5 inhibitor tng456 is being developed by Tango Therapeutics, Inc..
How many clinical trials involve prmt5 inhibitor tng456?
BioSniper tracks 1 clinical trial involving prmt5 inhibitor tng456.